Sanofi (SNY) stock — is it a good business?

Sanofi (SNY) stock — is it a good business? — InspectStocks

How it makes money

Prescription medicines
Vaccines

Competes with

What it sells5

Dupixent
A biologic medicine used for several conditions; the call mentions its approval for chronic spontaneous urticaria in children.
ALTUVIIIO
A medicine for hemophilia A, a disorder that affects blood clotting.
AYVAKIT
A medicine used to treat systemic mastocytosis, a rare disease.

Show 2 more

Sarclisa
A medicine for multiple myeloma, a cancer of plasma cells.
Wayrilz
A medicine approved in Japan for immune thrombocytopenia, a condition involving low levels of platelets in the blood.

Who buys it3

Patients receive Sanofi medicines through healthcare professionals who prescribe or administer them.
People receive Sanofi vaccines through healthcare providers and public health programs.
Pharmacies and clinics are involved in medicine access programs.

What it stands on, and what could break it

What the business leans on

1Dupixent is developed with Regeneron under an alliance that Sanofi describes as strategically important.
2Vaccine sales vary with seasonal demand, including the timing and strength of influenza seasons.
3Sanofi depends on clinical studies to show that medicines in development work well enough to advance.

What could go wrong

1Sanofi says its global business exposes it to increased risks in specific areas.
2Clinical setbacks have included failed or discontinued studies involving Dupixent in lichen simplex chronicus, venglustat in Fabry disease, and other pipeline medicines.
3Sanofi and Regeneron have ongoing litigation over information sharing, while discussions about future collaboration continue without a reported agreement.

Full financial statements →

About Sanofi

Sanofi makes prescription medicines and vaccines. Its medicines treat conditions including hemophilia A, systemic mastocytosis, and multiple myeloma. It also develops new medicines and vaccines through clinical trials.

Head office: Paris, France
Founded: 1973 (founding year, high)
Listed on: NYSE
Financial year ends: December 31

Built from Sanofi’s own filings with the U.S. Securities and Exchange Commission (SEC). Figures are as reported, with per-share history restated onto today’s share basis. This company files in EUR. Figures are converted to US dollars at $1.00 = 0.904810 EUR, the current rate, applied to every period alike — so growth and margins are the company’s own and not the exchange rate’s. This describes a business — it is not investment advice and not a recommendation to buy or sell anything.

Keep exploring

The themes Sanofi is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.

The theme it is part of

Highest-graded in Drug Manufacturers General

Graded A or B and worth $2B or more: A first, then the largest.

All 19 graded companies in its industry

Grade rose recently in Healthcare

Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.

All grade rises

How it makes money

Prescription medicines
Vaccines

Competes with

What it sells5

Dupixent
A biologic medicine used for several conditions; the call mentions its approval for chronic spontaneous urticaria in children.
ALTUVIIIO
A medicine for hemophilia A, a disorder that affects blood clotting.
AYVAKIT
A medicine used to treat systemic mastocytosis, a rare disease.

Show 2 more

Sarclisa
A medicine for multiple myeloma, a cancer of plasma cells.
Wayrilz
A medicine approved in Japan for immune thrombocytopenia, a condition involving low levels of platelets in the blood.

Who buys it3

Patients receive Sanofi medicines through healthcare professionals who prescribe or administer them.
People receive Sanofi vaccines through healthcare providers and public health programs.
Pharmacies and clinics are involved in medicine access programs.

What it stands on, and what could break it

What the business leans on

1Dupixent is developed with Regeneron under an alliance that Sanofi describes as strategically important.
2Vaccine sales vary with seasonal demand, including the timing and strength of influenza seasons.
3Sanofi depends on clinical studies to show that medicines in development work well enough to advance.

What could go wrong

1Sanofi says its global business exposes it to increased risks in specific areas.
2Clinical setbacks have included failed or discontinued studies involving Dupixent in lichen simplex chronicus, venglustat in Fabry disease, and other pipeline medicines.
3Sanofi and Regeneron have ongoing litigation over information sharing, while discussions about future collaboration continue without a reported agreement.

Full financial statements →

About Sanofi

Head office: Paris, France
Founded: 1973 (founding year, high)
Listed on: NYSE
Financial year ends: December 31

How it makes money

Competes with

What it sells5

Who buys it3

What it stands on, and what could break it

What the business leans on

What could go wrong

About Sanofi

Keep exploring

The theme it is part of

Highest-graded in Drug Manufacturers General

Grade rose recently in Healthcare

How it makes money

Competes with

What it sells5

Who buys it3

What it stands on, and what could break it

What the business leans on

What could go wrong

About Sanofi

Keep exploring

The theme it is part of

Highest-graded in Drug Manufacturers General

Grade rose recently in Healthcare

Big pharma

Sanofi

Growth & cash — 4 of 5

Business trend

Share price and grade over time

How it makes money

Competes with

What it sells5

Who buys it3

What it stands on, and what could break it

What the business leans on

What could go wrong

About Sanofi

Keep exploring

The theme it is part of

Highest-graded in Drug Manufacturers General

Grade rose recently in Healthcare

How it makes money

Competes with

What it sells5

Who buys it3

What it stands on, and what could break it

What the business leans on

What could go wrong

About Sanofi

Keep exploring

The theme it is part of

Highest-graded in Drug Manufacturers General

Grade rose recently in Healthcare

Big pharma

Sanofi

Past performance

Growth & cash — 4 of 5

Business trend

Share price and grade over time